AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1976678
Drug: Chlorhexidine preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine preparations
Trial: 487693
Drug: D-amphetamine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine, 10 mg orally
Trial: 487693
Drug: Pentazocine, 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine, 45 mg intramuscularly
Trial: 487693
Drug: Nefopam (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (both doses)
Trial: 31079746
Drug: No information
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No information treatment (control)
Trial: 27829323
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml of 6.7% maltodextrin solution (MALT)
Trial: 25135598
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (controlled lighting: lights on at 06:30 and off at 22:30, blue-enriched light in the morning, red-enriched light in the afternoon/evening)
Trial: 24252551
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (V.A.C.®)
Trial: 24252551
Drug: Standard conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conventional wound therapy
Trial: 17146380
Drug: 10 to
RxNorm normalized name: RE-10 Topical Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 to 100 mg/5 mL, 10 mL codeine/guaifenesin every 6 hours standing dose while awake
Trial: 2830407
Drug: RA‐233 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA‐233 plus chemotherapy
Trial: 31453490
Drug: Prolotherapy injections
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy injections (ultrasound-guided, 5 points, 3 times every 21 days)
Trial: 23660686
Drug: Bedtime medication
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime medication
Trial: 23660686
Drug: Morning medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning medication
Trial: 21937486
Drug: Thermostatic control
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermostatic control sterilisation programme (heating water to 65°C during 00:00‐06:00 h and to 50°C from 06:00 to 00:00 h daily)
Trial: 18335154
Drug: Bupivacaine injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine injection into the subcutaneous and muscular layers around the incision site
Trial: 17010727
Drug: Lidocaine jelly
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine jelly instillation (2 mL)
Trial: 8068604
Drug: Conventional immunoreactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunoreactive insulin assay
Trial: 8068604
Drug: Specific Linco
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific Linco insulin assay
Trial: 3284270
Drug: Alcuronium 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.03 mg/kg
Trial: 3284270
Drug: Alcuronium 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.03 mg/kg (3-min group)
Trial: 3284270
Drug: Alcuronium 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.03 mg/kg (2- and 3-min groups)
Trial: 9164003
Drug: b.i.d. group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. group: one capsule of slow‐release nicardipine, 20 mg, twice a day, three months
Trial: 9164003
Drug: t.i.d. group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t.i.d. group: one tablet of regular nicardipine, 20 mg, three times a day, three months
Trial: 6237116
Drug: Flutamide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (750 mg/day)
Trial: 6237116
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (100 mg/day)
Trial: 30762694
Drug: Single-injection bupivacaine
RxNorm normalized name: bupivacaine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection bupivacaine interscalene block with adjuvant clonidine, dexamethasone, and buprenorphine; multimodal analgesia including acetaminophen, NSAIDs, and opioids.
Trial: 27305512
Drug: Euclea natalensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euclea natalensis gel
Trial: 24310343
Drug: lutein/zeaxanthin, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lutein/zeaxanthin, 10 mg/2 mg
Trial: 22290953
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg TID on days 9 to 15
Trial: 22290953
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg BID on days 9 to 15
Trial: 22290953
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg TID on days 9 to 15
Trial: 22290953
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg TID on days 1 to 8
Trial: 22290953
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses (400 mg BID and 400 mg TID)
Trial: 15751772
Drug: Nevirapine (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine (once or twice daily)
Trial: 15751772
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with lamivudine and stavudine
Trial: 11892685
Drug: Homeopathic Arnica
RxNorm normalized name: ARNICA MONTANA WHOLE 6 [hp_X] ORAL LOZENGE [Homeopathic Arnica Drops]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic Arnica tablets and herbal Arnica ointment
Trial: 10459957
Drug: Zidovudine 300
RxNorm normalized name: zidovudine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine 300 mg tablet twice daily from 36 weeks' gestation and every 3 h from onset of labour until delivery
Trial: 7887759
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (unrelated discussion on non-steroidal drug use)
Trial: 3896278
Drug: Nicardipine 30
RxNorm normalized name: niCARdipine 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 30 mg three times daily
Trial: 111886
Drug: High-dose intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intermittent subcutaneous injections
Trial: 25801095
Drug: Intravenous peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous peginterferon alfa-2a 180 μg, once weekly for 2 weeks
Trial: 25801095
Drug: Intravenous peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous peginterferon alfa-2a 180 μg, twice weekly for 2 weeks
Trial: 25801095
Drug: Subcutaneous peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous peginterferon alfa-2a 180 μg, once weekly for 2 weeks
Trial: 25801095
Drug: Subcutaneous peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous peginterferon alfa-2a 180 μg, twice weekly for 2 weeks
Trial: 16713391
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of industrially produced TFA (IP‐TFA)
Trial: 16713391
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g n‐3 PUFA
Trial: 11425821
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg injection of triptorelin (group 1)
Trial: 11425821
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg triptorelin daily reduced to 50 microg at the start of FSH stimulation (group 2)
Trial: 3304156
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin
Trial: 27711918
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with laser treatment
Trial: 21706324
Drug: Cisplatin 25
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/m² intravenously on days 1-3 and gemcitabine 1,000 mg/m² on days 1 and 8, every 3 weeks for two cycles as neoadjuvant chemotherapy, followed by two cycles as adjuvant chemotherapy after radiotherapy.
Trial: 21706324
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy
Trial: 20167174
Drug: Paradigm Veo
RxNorm normalized name: Veopoz
DrugBank: Pozelimab (DB15218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paradigm Veo insulin pump with new calibration algorithm
Trial: 18175748
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g vitamin C daily supplementation in humans
Trial: 18175748
Drug: 0.24 mg/cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.24 mg/cm2 body surface area vitamin C daily supplementation in rats
Trial: 2859523
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (4000 or 4800 rad)
Trial: 2859523
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (fluorouracil and semustine [methyl‐CCNU])
Trial: 2859523
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiation therapy and chemotherapy
Trial: 2859523
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy (control group)
Trial: 25348047
Drug: Conventional intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional intensive insulin therapy (CIIT)
Trial: 24510314
Drug: Hepatic intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hepatic intra-arterial fotemustine (HIA) at 100 mg/m² on days 1, 8, 15 (and 22 in HIA arm only) as induction, and after a 5-week rest period every 3 weeks as maintenance.
Trial: 24510314
Drug: Intravenous fotemustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fotemustine (IV) at 100 mg/m² on days 1, 8, 15 as induction, and after a 5-week rest period every 3 weeks as maintenance.
Trial: 22300292
Drug: Retinal regeneration
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinal regeneration therapy laser
Trial: 15956273
Drug: Galantamine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (16 mg, 24 mg, or 32 mg daily)
Trial: 2169587
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin (100 mg/m² on days 1 and 29) and vinblastine (5 mg/m² on days 1, 8, 15, 22, and 29) followed by radiation therapy (60 Gy over 6 weeks)
Trial: 2169587
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy alone (60 Gy over 6 weeks)
Trial: 2169587
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin and vinblastine
Trial: 30747964
Drug: Paracetamol (acetaminophen)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (acetaminophen) 1000 mg plus ibuprofen 400 mg (PCM + IBU)
Trial: 30747964
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg (PCM)
Trial: 30747964
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg (IBU)
Trial: 30747964
Drug: Half-strength paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-strength paracetamol 500 mg plus ibuprofen 200 mg (HS-PCM + IBU)
Trial: 30747964
Drug: Paracetamol (PCM)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (PCM) alone
Trial: 30747964
Drug: Half-strength paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-strength paracetamol plus ibuprofen (HS-PCM + IBU)
Trial: 30747964
Drug: Ibuprofen alone
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen alone (IBU)
Trial: 30747964
Drug: Paracetamol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol alone (PCM)
Trial: 30747964
Drug: Groups receiving
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups receiving ibuprofen (IBU)
Trial: 19999017
Drug: Salbutamol and
RxNorm normalized name: salbutamol and budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol and ipratropium bromide administered by device of measured doses and space chamber
Trial: 14981346
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg once daily + ASA 75 mg once daily
Trial: 9511113
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice daily for 2 to 3 weeks)
Trial: 9511113
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (250 mg twice daily for 2 to 3 weeks)
Trial: 7974935
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day propiverine
Trial: 7974935
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day propiverine
Trial: 7974935
Drug: 45 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/day propiverine
Trial: 7974935
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day propiverine
Trial: 7974935
Drug: Propiverine (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine (doses of 15, 30, 45 and 60 mg/day)
Trial: 4908342
Drug: 1-adamantanamine hydrochloride
RxNorm normalized name: 1-adamantanamine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-adamantanamine hydrochloride (aminoadamantane) 100 mg every 12 hours for 10 days
Trial: 28477414
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin therapy
Trial: 28477414
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin therapy
Trial: 28477414
Drug: Prandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prandial insulin therapy
Trial: 23648946
Drug: Ambrisentan, 10
RxNorm normalized name: Ambrisentan, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan, 10 mg/d
Trial: 19826286
Drug: Low-load resistance
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-load resistance training with slow movement and tonic force generation (LST) at approximately 60% 1RM, 3-second lifting, and 3-second lowering, performed twice a week for 13 weeks
Trial: 19826286
Drug: High-intensity exercise
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity exercise at normal speed (HM) at 85% 1RM, 1-second lifting, 1-second lowering, and 1-second relaxed movement, performed twice a week for 13 weeks
Trial: 11579330
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg of morphine following induction and placebo saline during peritoneal closure
Trial: 11579330
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline following induction and 0.15 mg/kg of morphine during peritoneal closure
Trial: 26296862
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol administered via dry powder inhalers
Trial: 21604899
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment for GAD patients
Trial: 21604899
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment for GAD patients (Overly Nurturant subtype)
Trial: 21604899
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment for GAD patients (Intrusive subtype)
Trial: 21604899
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment for GAD patients (Socially Avoidant subtype)
Trial: 21604899
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment for GAD patients (Nonassertive subtype)
Trial: 12625833
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen (CEE; 0.625 mg/day; n = 14)
Trial: 12625833
Drug: Raloxifene (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (150 mg/day; n = 13)
Trial: 10658376
Drug: Heparin-bonded circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded circuit
Trial: 8557867
Drug: 0.25 g
RxNorm normalized name: AMICAR 0.25 GM/mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g nitrogen (N)/kg Ideal Body Weight (IBW)
Trial: 8557867
Drug: 0.12 g
RxNorm normalized name: OLIVE OIL 0.12 g in 10 mL VAGINAL SPRAY [MediORO W]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 g nitrogen (N)/kg Ideal Body Weight (IBW)
Trial: 8557867
Drug: 0.18 g
RxNorm normalized name: MENTHOL 0.18 g in 100 TOPICAL GRANULE [Cough Drops]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.18 g nitrogen (N)/kg Ideal Body Weight (IBW)
Trial: 2128866
Drug: Colestyramine 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestyramine 16 g
Trial: 488523
Drug: sulphinpyrazone (600‐800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphinpyrazone (600‐800 mg daily)
Trial: 25860005
Drug: Bicyclol 75
RxNorm normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicyclol 75 mg/day (25 mg three times daily) in conjunction with glucurolactone 600 mg/day (200 mg three times daily)
Trial: 25860005
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving glucurolactone 600 mg/day (200 mg three times daily) only
Trial: 15789978
Drug: Oral‐B Indicator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Indicator toothbrush
Trial: 11748775
Drug: haloperidol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (0.5 to 2 mg/day)
Trial: 11748775
Drug: risperidone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone (0.5 to 2 mg/day)
Trial: 9597563
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine suppositories (MSC-R)
Trial: 9597563
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine tablets (MSC-T)
Trial: 29705451
Drug: Barberry juice
RxNorm normalized name: bilberry juice extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barberry juice (BJ), 200 ml daily for 8 weeks
Trial: 28006831
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (melt and tablets)
Trial: 26037429
Drug: Double-fortified salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-fortified salt (DFS) containing 47 mg of potassium iodate and 3300 mg of microencapsulated ferrous fumarate (1100 mg elemental iron) per kg of salt
Trial: 16788299
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose ASA+MR-DP (b.i.d. on days 5-28)
Trial: 16788299
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose ASA+MR-DP (once daily before bed during days 5-14, b.i.d. on days 15-28)